

Cont  
A2  
Sub  
B2

6. (Amended) A method of claim 5, wherein the angiotensin converting enzyme inhibitor is alacepril, alatriopril, altiopril calcium, ancovenin, benazepril, benazepril hydrochloride, benazeprilat, benzoylcaptopril, captopril, captopril-cysteine, captopril-glutathione, ceranapril, ceranopril, ceronapril, cilazapril, cilazaprilat, delapril, delapril-diacid, enalapril, enalaprilat, enapril, epicaptopril, foroxymithine, fosfenopril, fosenopril, fosenopril sodium, fosinopril, fosinopril sodium, fosinoprilat, fosinoprilic acid, glycopril, hemorphin-4, idrapril, imidapril, indolapril, indolaprilat, libenzapril, lisinopril, lyciumin A, lyciumin B, mixanpril, moexipril, moexiprilat, moveltipril, muracein A, muracein B, muracein C, pentopril, perindopril, perindoprilat, pivalopril, pivopril, quinapril, quinapril hydrochloride, quinaprilat, ramipril, ramiprilat, spirapril, spirapril hydrochloride, spiraprilat, spiropril, spiropril hydrochloride, temocapril, temocapril hydrochloride, teprotide, trandolapril, trandolaprilat, utibapril, zabicipril, zabiciprilat, zofenopril, or zofenoprilat.

Sub  
C1

7. (Amended) The method of claim 6, wherein the angiotensin converting enzyme inhibitor is ramipril, ramiprilat, lisinopril, enalapril, or enalaprilat.

8. (Amended) The method of claim 5, wherein the angiotensin II antagonist is candesartan, candesartan cilexetil, losartan, valsartan, irbesartan, tasosartan, telmisartan, or eprosartan.

9. (Amended) The method of claim 8, wherein the angiotensin II antagonist is candesartan, or candesartan cilexetil.

10. (Amended) A pharmaceutical composition for preventing congestive heart failure in a patient not previously having congestive heart failure and who has an essentially maintained heart function, comprising a therapeutically effective amount of an inhibitor of the renin-angiotensin system to prevent the congestive heart failure in the patient and a pharmaceutically acceptable carrier.

11. (Amended) A pharmaceutical composition of claim 10, wherein the inhibitor of the renin-angiotensin system is an angiotensin converting enzyme inhibitor, or an angiotensin II type 1 receptor antagonist.